Ibuprofen recall: Ibuflam 600 batch pulled after metal foreign body found
ibuprofen is at the center of a product quality alert after Zentiva recalled a complete batch of its painkiller Ibuflam Lichtenstein 600 mg film-coated tablets when a metallic foreign body was discovered in a pack.
The recall concerns Ibuflam 600 in a 50-tablet pack and is tied to batch number 5R02514. Zentiva described the action as a precaution taken in coordination with the responsible supervisory authority, with the request directed to wholesalers and pharmacies rather than directly to patients.
What happens when Ibuprofen tablets are recalled at wholesale and pharmacy level?
Zentiva’s recall is not being carried out on the patient level. Instead, pharmacies and wholesalers are being asked to check stock and return affected packs. The trigger for the action was the detection of a metallic foreign body in a single tablet.
In practical terms, returns from pharmacies are handled through the wholesale channel. Zentiva characterized patient-level replacement for quality complaints as a standard process and a goodwill arrangement that does not burden statutory health insurers, while remaining at the discretion of the pharmacy.
A key condition is process-related: the pharmacy should not provide a replacement entirely on its own initiative. The quality complaint needs to be reported to Zentiva, and any replacement should be provided after consultation and on Zentiva’s instruction. Zentiva noted that this standard process is subject to regular inspections by supervisory authorities.
What if patients already have the affected Ibuflam batch at home?
Even though the recall is not addressed directly to patients, patients can still seek a remedy through the normal handling of quality complaints. Zentiva stated that there is generally always an option to obtain a replacement through the dispensing pharmacy when there is suspicion of a quality defect—while noting that, in this case, suspicion relating to the batch is considered justified.
Zentiva also drew a distinction between replacement within a quality-complaint process and an “Ersatzverfahren” re-dispensing: replacing a previously dispensed, potentially defective medicine is treated as a 1: 1 exchange tied to the pharmaceutical company’s duty of care and traffic safety obligations. Zentiva referenced the legal framework connected to the German Medicines Act (AMG) and the Ordinance on the Manufacture of Active Pharmaceutical Ingredients (AmWHV) in relation to quality defects and associated risks.
Zentiva further noted that when a pack is nearly used up, the standard replacement process may not be appropriate in some circumstances, since that situation could require a new prescription.
What happens when metal foreign bodies enter consumer products?
The Ibuflam case arrives amid broader attention to metal contamination in consumer goods. A food specialist, Sabrina Göddertz, representative in the Food team at Verbraucherzentrale Bundesverband e. V. , described metal parts in foods as a serious health hazard.
From a medical perspective, Dr. Daniel Benten, Chief Physician for Gastroenterology and Hepatology at Asklepios Klinikum Harburg, explained that very small particles can pass the stomach gatekeeper, while elongated and sharp foreign bodies carry a higher risk of complications. He described how the esophagus and stomach may suffer superficial mucosal lesions, but such objects can perforate the thin wall of the small intestine, potentially leading to an abscess.
For now, Zentiva has not publicly detailed the cause in the tablet case. The immediate action remains focused on identifying and removing affected stock from the wholesale and pharmacy supply chain, while allowing patients who suspect a defect in their pack to approach their pharmacy for a potential 1: 1 replacement under the quality-complaint process.
